AF
PTLA

Advisornet Financial’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Advisornet Financial’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed -$3K – 1843
2019
Q1 		$3K Buy
+100
New +$2.88K ﹤0.01% 1399

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Advisornet Financial's PTLA Position: Q2 2019 in Review

Advisornet Financial sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2019, closing a stake of 100 shares — an estimated $3K sold.

Advisornet Financial first reported a position in PTLA in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 202 funds tracked by Wall St. Rank hold PTLA as of Q2 2019.

  • Advisornet Financial reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Advisornet Financial sold 100 Portola Pharmaceuticals, Inc. shares in Q2 2019, an estimated $3K.
  • Advisornet Financial first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Advisornet Financial's Portola Pharmaceuticals, Inc. position peaked at $3K in Q1 2019.
  • 202 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2019.

Based on Advisornet Financial's 13F filing for Q2 2019, filed 15 Jul 2019.